Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • biocon

    Tag: Biocon

    You Searched For "biocon"
    Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility

    Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility

    Medical Dialogues Bureau1 April 2020 12:44 PM IST
    Bengaluru: Biocon Sdn Bhd, a subsidiary of Biocon Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S....
    Biocon, Mylan win patent rights for Insulin Glargine Device against Sanofi

    Biocon, Mylan win patent rights for Insulin Glargine Device against Sanofi

    Medical Dialogues Bureau12 March 2020 11:29 AM IST
    Insulin Glargine is a long-acting insulin used to treat adults with Type 2 diabetes and adults and paediatric patients with Type 1 diabetes for the...
    USFDA Accepts Biocon, Mylans application for review of   Proposed Biosimilar of Bevacizumab

    USFDA Accepts Biocon, Mylan's application for review of Proposed Biosimilar of Bevacizumab

    Medical Dialogues Bureau10 March 2020 1:15 PM IST
    Biocon Ltd. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...
    Biocon Small Molecules API Manufacturing Facility Completes Post -Approval and GMP USFDA Inspection

    Biocon Small Molecules API Manufacturing Facility Completes Post -Approval and GMP USFDA Inspection

    Medical Dialogues Bureau29 Feb 2020 11:35 AM IST
    New Delhi: Drug API maker, Biocon has informed that the U.S. Food and Drug Administration (FDA) conducted a Post-Approval and GMP inspection of Small...
    Biocons Insulin Manufacturing Facility in Malaysia Completes USFDA inspection with three observations

    Biocon's Insulin Manufacturing Facility in Malaysia Completes USFDA inspection with three observations

    Medical Dialogues Bureau24 Feb 2020 12:11 PM IST
    Malaysia:Drug major Biocon recently informed about the USFDA inspection at its Insulin Manufacturing Facility in Malaysia, and that the agency issued...
    Niti Aayog meets Top pharma execs to find ways to mitigate coronavirus impact; DoP seeks export ban on 12 APIs

    Niti Aayog meets Top pharma execs to find ways to mitigate coronavirus impact; DoP seeks export ban on 12 APIs

    Medical Dialogues Bureau21 Feb 2020 11:58 AM IST
    The meeting was attended by Biocon's Kiran Mazumdar Shaw, Zydus' Pankaj Patel and Dr Reddy's Laboratories' Satish Reddy and other top pharma execs
    Primary healthcare can play key role in combating outbreaks like coronavirus: Biocon Chief Kiran Mazumdar-Shaw

    Primary healthcare can play key role in combating outbreaks like coronavirus: Biocon Chief Kiran Mazumdar-Shaw

    Medical Dialogues Bureau20 Feb 2020 2:17 PM IST
    New Delhi: Biocon Chairperson and MD Kiran Mazumdar-Shaw on Wednesday stressed the need for having an effective primary healthcare system saying it...
    Minister inaugurates Syngene new RnD centre in Hyderabad

    Minister inaugurates Syngene new RnD centre in Hyderabad

    Medical Dialogues Bureau18 Feb 2020 4:19 PM IST
    This is Syngene International Ltd.'s first operational research centre outside Bengaluru. When fully commissioned by the end of this year at an...
    USFDA issues Form 483 with 5 observations to Biocon Bengaluru facility

    USFDA issues Form 483 with 5 observations to Biocon Bengaluru facility

    MD bureau28 Jan 2020 2:24 PM IST
    New Delhi: Biocon Ltd on Monday said the US health regulator conducted a pre-approval inspection and good manufacturing practice (GMP) examination of...
    Biocon Biologics gets Rs 536 crore investment from True North Fund

    Biocon Biologics gets Rs 536 crore investment from True North Fund

    Farhat Nasim22 Jan 2020 1:09 PM IST
    New Delhi: Biocon recently announced that Biocon Biologics India has received the subscription money aggregating to Rs. 536.25 crore from Activ Pine...
    Biocon Bengaluru facility clears USFDA inspection

    Biocon Bengaluru facility clears USFDA inspection

    Farhat Nasim21 Jan 2020 1:00 PM IST
    The US Food and Drug Administration (USFDA) conducted a pre-approval inspection of the oral solid dosage manufacturing facility of Biocon Pharma, a...
    Biocon chief Kiran Mazumdar Shaw bags Order Of Australia honour

    Biocon chief Kiran Mazumdar Shaw bags Order Of Australia honour

    Medical Dialogues Bureau20 Jan 2020 12:00 PM IST
    Kiran Mazumdar Shaw, Biocon founder and an Australian Global Alumni Ambassador, is also recognised for her sustained and significant contribution to...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok